Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata – a large retrospective study on 142 patients with a self‐controlled design

Ohlmeier, M; Traupe, Horst; Luger, T A; Böhm, Markus

doi:10.1111/j.1468-3083.2011.04114.x

Cited by 55 publications

(65 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Freyschmidt-Paul et al ., 2003)(Ohlmeier et al ., 2012) A smaller number of studies have been conducted to investigate immune alterations induced in scalp that is associated with hair regrowth. Identified effects of DPCP include decreasing CD4+ T-cell but increasing CD8+ T-cell infiltrates.…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights

Gulati

Suárez‐Fariñas

Fuentes‐Duculan

et al. 2014

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. It is used as an immune modulating therapeutic, but its molecular effects in human skin are largely unknown. We studied cellular and molecular characteristics of a recall response to 0.04% DPCP at 3 day (peak) and 14 day (resolution) timepoints using immune markers, RT-PCR and gene array approaches. A peak response showed modulation of ~7,500 mRNA transcripts, with high expression of cytokines that define all major effector T-cell subsets. Concomitant increases in T-cell and CD11c+ dendritic cell (DC) infiltrates were measured. The resolution reaction was characterized by unexpectedly high levels of T-cells and mature (DC-LAMP+) DCs, but with marked decreases in expression of IL-2, IFNγ, and other T-cell derived cytokines. However, negative immune regulators such as IDO1 that were high in peak reactions, continued to have high expression in resolution reactions. In the resolution reaction, ~1,500 mRNA transcripts were significantly different from placebo-treated skin. These data suggest the response to DPCP evolves from an inflammatory/effector peak at day 3 to a more regulated immune response after 14 days. This model system could be useful for further dissection of mechanisms of immune activation or negative immune regulation in human skin.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights

Gulati

Suárez‐Fariñas

Fuentes‐Duculan

et al. 2014

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Patients were sensitized with 2% DPCP, followed by weekly increases of DPCP applied to the affected areas titrated up to a maximum of 3% for 3 months. The authors reported >90% terminal hair regrowth in 72.7% of AT and 84.6% of AU participants, which was the highest success rate of all DPCP studies found in this search . DPCP showed no adverse events other than temporary skin changes such as localized erythema and irritation.…”

Section: Resultsmentioning

confidence: 64%

“…The largest retrospective study was performed by Ohlmeier et al . and included 142 AA patients, 28 of whom had AT or AU . Patients were sensitized with 2% DPCP, followed by weekly increases of DPCP applied to the affected areas titrated up to a maximum of 3% for 3 months.…”

Section: Resultsmentioning

confidence: 99%

“…Although none of the therapies outlined in this review were 100% successful, some have shown promising results. In particular, in the category of topical immunotherapy, successful response rates were as high as 84% in AU patients treated with DPCP and 64% with SADBE . The majority of steroid trials reviewed examined systemic, rather than topical administration and resulted in low to excellent success rates (ranging from 9 to 100%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Review of treatment for alopecia totalis and alopecia universalis

et al. 2017

View full text Add to dashboard Cite

Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. This review focuses on the evidence for current treatment options for AT and AU. The PubMed database was searched from January 1, 2000, to September 1, 2016, for clinical trials, retrospective studies, and case reports of treatments for AT and AU. A total of 40 studies were retrieved and analyzed. Therapies studied for AT/AU included: topical immunotherapy, steroids, photodynamic therapy, immunosuppressive agents, TNFα inhibitors, and other therapies, such as sulfasalazine, bexarotene, JAK inhibitors, and simvastatin/ezetimibe. Although certain treatments showed significant hair regrowth, no treatment was completely effective. The most promising therapies with the highest quality data include diphenylcyclopropenone, squaric acid dibutylester, photodynamic therapy, steroids, and cyclosporine in combination with methylprednisolone. High-quality randomized-controlled trials with large sample sizes are lacking. Unified outcome guidelines are encouraged to facilitate the comparison of future studies.

show abstract

“…En el añ o 2012 aparece un trabajo con 142 pacientes, de los cuales 51 obtienen una repoblació n completa, y 20 una respuesta parcial considerable 13 .…”

Section: Inmunoterapia De Contactounclassified

Tratamiento de la alopecia areata

Gutiérrez

Ruiz‐Villaverde

2013

Piel

View full text Add to dashboard Cite

Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata – a large retrospective study on 142 patients with a self‐controlled design

Cited by 55 publications

References 23 publications

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights

Molecular Characterization of Human Skin Response to Diphencyprone at Peak and Resolution Phases: Therapeutic Insights

Review of treatment for alopecia totalis and alopecia universalis

Tratamiento de la alopecia areata

Contact Info

Product

Resources

About